Bone Biologics Corp

For the period ended Mar 31, 2024. Filed May 14, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 14, 2024

BBLG$0.34+3.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Unaudited Condensed Consolidated Balance Sheets

Condensed Consolidated Balance Sheets

	March 31, 2024	December 31, 2023
Assets
Current Assets
Cash	$3,227,634	$3,026,569
Advances on research and development contract services	328,844	328,844
Prepaid insurance	273,096	372,350
Prepaid expenses	10,000	10,000
Total current assets	3,839,574	3,737,763
Total assets	$3,839,574	$3,737,763
Liabilities and Stockholders’ Equity
Current Liabilities
Accounts payable and accrued expenses	$146,186	$360,662
Accrued legal settlement	-	414,989
Warrant liability	18,440	55,751
Total current liabilities	164,626	831,402
Total liabilities	164,626	831,402
Commitments and Contingencies	-	-
Stockholders’ Equity
Preferred Stock, $0.001 par value per share; 20,000,000 shares authorized; none issued or outstanding at March 31, 2024 and December 31, 2023	-	-
Common stock, $0.001 par value per share; 100,000,000 shares authorized; 1,016,489 and 534,238 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	1,016	534
Additional paid-in capital	85,448,860	83,814,785
Accumulated deficit	(81,774,928)	(80,908,958)
Total stockholders’ equity	3,674,948	2,906,361
Total liabilities and stockholders’ equity	$3,839,574	$3,737,763

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.